(2010; 32 pages)
Globally more than 4.4 Trillions US$ is spent on health services each year. Such large amounts of money are an attractive target for abuse, corruption and unethical practices. In fact, experts estimate that up to quarter of procurement spending on medicine is lost because of corruption and bad governance, and millions of people living in the poorest countries will suffer; as resources that could be used to buy medicines or recruit much –needed health professionals are wasted as a result of corruption, which reduces the availability of essential medicines and can cause prolonged illness and even deaths.
In 2004, WHO established the Good Governance for medicines (GGM) programme. The programme’s goal is to reduce corruption in pharmaceutical systems through the application of transparent accountable administrative procedures and the promotion of ethical practices.
The GGM is implemented in a 3-steps approach: Phase I, “Measuring transparency in the public pharmaceutical sector” provides us with a comprehensive picture of the level of transparency and the vulnerability to corruption in key functions of the pharmaceutical sector. The 2nd phase includes the development of this document “Jordan Framework for Good Governance in the Pharmaceutical Sector” after wide consultation with key stakeholders. The 3rd phase is the phase of implementation the national program of good governance and institutionalizing it in the pharmaceutical sector.
This framework includes methodological goals, and expected outputs of the program, in which good governance, its requirements and characteristics are defined. In addition, it includes international anticorruption initiatives and conventions as well as procedures and initiatives carried out in Jordan. The results of the transparency assessment were completed in 2007 and have been discussed as well as the functions that can be vulnerable to corruption. Based on this, a work plan has been prepared to guarantee the application of recommendations in the assessment phase...